Clinical trial sites need a proactive compliance strategy

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Food and drug administration

Clinical trial sites must take a proactive approach to non-compliance by identifying risks and having corrective action plans, says a former FDA investigator.

Inspection capacity limitations caused, in part, by globalisation are shifting oversight responsibility from regulators to industry. In this environment the US Food and Drug Administration (FDA), and other regulators, will increasingly expect clinical trial sites to understand and mitigate their risks.

FDA warning letters hint at this new approach, which wants trial sites to take a proactive approach to non-compliance, said Tamera Norton Smith, president and senior consultant of Norton Audits.

Clinical trial sites should understand, and communicate to the FDA, their compliance risks and how they will respond if these events occur. Increasingly the FDA is asking if problems are being responded to in real-time, said Smith.

The next step is self-reporting of compliance events. Smith expects the FDA to make self-reporting mandatory in the future and recommends companies put the system in place before this occurs.

Internal communication must also improve. Companies sometimes fail to effectively use audit information, said Smith, in part because of shortcomings in communicating findings to executive management.

Five failings

By analysing recent feedback from the FDA Smith has identified the five most common compliance issues. The main deficiency is failure to make sure proper monitoring of clinical investigations.

Globalisation of clinical trials makes monitoring more challenging and although companies are spending money on the problem it is often ineffectively used, said Smith. Compliance problems are normally identified by companies, but responses are ineffective

Failure to make sure a trial is conducted in accordance with the general investigational plan and protocol is the second most common problem. This failing is very easy for investigators to spot, said Smith, and can be caused by unrealistic protocols.

The last three common problems are failure to make sure investigators: work in compliance with the study plan and FDA regulations; have the necessary training and experience; and are provided with the information to do the trial.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Related suppliers

Follow us

Products

View more

Webinars